The phase 3, open-label, randomized ALINA trial randomized 257 patients with completely resected stage IB (≥4 cm)-IIIA (AJCC VII edition) ALK-positive NSCLC to receive 2 years of adjuvant alectinib vs. four cycles of platinum-based chemotherapy [30]. This evidence concerns the gene ALK and non-small cell lung carcinoma.